CCM
KRTX

CAAS Capital Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

CAAS Capital Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-20,511
Closed -$2.34M – 1159
2021
Q2 		$2.34M Sell
20,511
-358,094
-95% -$41.9M 0.04% 370
2021
Q1 		$45.5M Buy
+378,605
New +$42.9M 0.49% 34

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

CAAS Capital Management's KRTX Position: Q3 2021 in Review

CAAS Capital Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q3 2021, closing a stake of 20,511 shares — an estimated $2.34M sold.

CAAS Capital Management first reported a position in KRTX in Q1 2021 and held it in 2 quarters. The position peaked at $45.5M in Q1 2021. 159 funds tracked by Wall St. Rank hold KRTX as of Q3 2021.

  • CAAS Capital Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • CAAS Capital Management sold 20,511 Karuna Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $2.34M.
  • CAAS Capital Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • CAAS Capital Management's Karuna Therapeutics, Inc. Common Stock position peaked at $45.5M in Q1 2021.
  • 159 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2021.

Based on CAAS Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.